Apparent mineralocorticoid excess

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:320OMIM:218030E26.8
Who is this for?
Show terms as
19Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Apparent mineralocorticoid excess (AME) is a rare inherited condition that affects how the body regulates blood pressure and salt balance. In a healthy body, a hormone called cortisol is normally broken down by an enzyme called 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2). In people with AME, this enzyme does not work properly, so cortisol builds up in the kidneys and acts like a different hormone called aldosterone. This tricks the kidneys into holding onto too much salt and water, which causes very high blood pressure (hypertension) from an early age, along with low levels of potassium in the blood. The condition is also sometimes called syndrome of apparent mineralocorticoid excess or 11β-HSD2 deficiency. It is caused by changes (mutations) in the HSD11B2 gene and is passed down through families in an autosomal recessive pattern, meaning a child must inherit a faulty copy of the gene from both parents to develop the disease. Without treatment, AME can lead to serious complications including stroke, heart problems, and kidney damage. Treatment focuses on lowering blood pressure and blocking the harmful effects of excess cortisol on the kidneys. With proper management, outcomes can be significantly improved, though lifelong treatment is usually needed.

Also known as:

Key symptoms:

Very high blood pressure, often starting in childhoodLow potassium levels in the blood (hypokalemia)Muscle weakness or cramps due to low potassiumExcessive thirst and frequent urinationSlow growth or short stature in childrenFatigue and general tirednessHeadachesSwelling in the body (edema)Kidney damage over timeHeart enlargement due to long-standing high blood pressureStroke or other cardiovascular complications in severe or untreated cases

Clinical phenotype terms (17)— hover any for plain English
Decreased circulating renin concentrationHP:0003351Hypokalemic metabolic alkalosisHP:0001960Decreased circulating aldosterone concentrationHP:0004319Abnormality of circulating cortisol levelHP:0011731Abnormal urine sodium concentrationHP:0012603Hypertensive retinopathyHP:0001095Renal sodium wastingHP:0012606
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Apparent mineralocorticoid excess.

View clinical trials →

No actively recruiting trials found for Apparent mineralocorticoid excess at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Apparent mineralocorticoid excess community →

Specialists

19 foundView all specialists →
JM
Joshua A Beckman, MD
ENCINITAS, CA
Specialist
PI on 1 active trial
JP
Jorge A Pérez
Specialist
2 Apparent mineralocorticoid excess publications
KY
Kun-Qi Yang
Specialist
1 Apparent mineralocorticoid excess publication
XZ
Xian-Liang Zhou
Specialist
1 Apparent mineralocorticoid excess publication
FP
Fan Peng
DALLAS, TX
Specialist
1 Apparent mineralocorticoid excess publication
HJ
Huan-Huan Ji
Specialist
1 Apparent mineralocorticoid excess publication
NZ
Ni Zhang
Specialist
1 Apparent mineralocorticoid excess publication
BH
Ben-Nian Huo
Specialist
1 Apparent mineralocorticoid excess publication
CC
Cristian A Carvajal
Specialist
3 Apparent mineralocorticoid excess publications
AT
Alejandra Tapia-Castillo
Specialist
3 Apparent mineralocorticoid excess publications
CF
Carlos E Fardella
Specialist
3 Apparent mineralocorticoid excess publications
YL
Yi-Ting Lu
Specialist
1 Apparent mineralocorticoid excess publication
DZ
Di Zhang
BOSTON, MA
Specialist
1 Apparent mineralocorticoid excess publication
QZ
Qiong-Yu Zhang
Specialist
1 Apparent mineralocorticoid excess publication
ZZ
Ze-Ming Zhou
Specialist
1 Apparent mineralocorticoid excess publication
MM
Maria I. New, MD
BELLS, TN
Specialist
PI on 2 active trials
RG
Rousseau Gama
Specialist
PI on 2 active trials7 Apparent mineralocorticoid excess publications
XT
Xue-Wen Tang
Specialist
1 Apparent mineralocorticoid excess publication
MM
Maria Palmisano, M.D.
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Apparent mineralocorticoid excess.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Apparent mineralocorticoid excessForum →

No community posts yet. Be the first to share your experience with Apparent mineralocorticoid excess.

Start the conversation →

Latest news about Apparent mineralocorticoid excess

No recent news articles for Apparent mineralocorticoid excess.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is my target blood pressure, and how will we know if treatment is working?,How often do I need blood tests to check my potassium and kidney function?,Should my siblings or other family members be tested for this condition?,Are there any dietary changes I should make, such as reducing salt?,What are the warning signs that I should go to the emergency room?,Is kidney transplantation something I should consider, and what are the criteria?,Are there any clinical trials or new treatments I should know about?

Common questions about Apparent mineralocorticoid excess

What is Apparent mineralocorticoid excess?

Apparent mineralocorticoid excess (AME) is a rare inherited condition that affects how the body regulates blood pressure and salt balance. In a healthy body, a hormone called cortisol is normally broken down by an enzyme called 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2). In people with AME, this enzyme does not work properly, so cortisol builds up in the kidneys and acts like a different hormone called aldosterone. This tricks the kidneys into holding onto too much salt and water, which causes very high blood pressure (hypertension) from an early age, along with low levels of potas

How is Apparent mineralocorticoid excess inherited?

Apparent mineralocorticoid excess follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Apparent mineralocorticoid excess typically begin?

Typical onset of Apparent mineralocorticoid excess is childhood. Age of onset can vary across affected individuals.

Which specialists treat Apparent mineralocorticoid excess?

19 specialists and care centers treating Apparent mineralocorticoid excess are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.